

March 10, 2022

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Atsushi Udoh, President and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department (TEL: 81-3-6838-2803)

Notice Regarding Share Acquisition of AYM HD KK

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh; hereinafter “TOHO HOLDINGS”) hereby announces that it has acquired a part of shares of AYM HD KK from BCP Asia AYM Holding (Cayman) L.P. as outlined below. AYM HD KK owns all shares of AYUMI Pharmaceutical Holdings.

1. Reason for the Share Acquisition

TOHO HOLDINGS is a corporate group active in medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the corporate slogan “Total Commitment to Good Health”. TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

Meanwhile, AYUMI Pharmaceutical Corporation (hereinafter “AYUMI Pharmaceutical”), a wholly owned subsidiary of AYUMI Pharmaceutical Holdings, continues its daily activities to realize a “pain-free life” and a “bright future” for patients under the management philosophy of “improving people’s quality of life and contributing to the future of healthcare in Japan as a rheumatism and orthopedics specialty pharma company.”

AYUMI Pharmaceutical has a product portfolio including market-leading products, such as Etanercept used to treat rheumatoid arthritis and related conditions and Calonal used in the field of orthopedics, which account for more than 50% of total sales. With the use of biosimilars (BS) expected to accelerate for the treatment of rheumatoid arthritis from this point onward, AYUMI Pharmaceutical is likely to see growth in its business driven by the introduction and launch of new BS products. In the orthopedic field, meanwhile, sales of mainstay product Calonal are anticipated to grow steadily, supported by an increase in the acetaminophen selection rate and the spread of appropriate analgesic prescription doses. Furthermore, considering that AYUMI Pharmaceutical continues efforts to explore the fields of osteoporosis and osteoarthritis of the knee, the need for its products is expected to increase in the super-aged society.

Through this acquisition of shares, TOHO HOLDINGS will further strengthen its ties with AYUMI Pharmaceutical and continue to strive for a stable supply of AYUMI Pharmaceutical’s products as before by utilizing its extensive and strong business relationships with medical institutions across the country. In addition, through this acquisition of shares, we will deepen our knowledge about BS products and deliver them to patients on a more stable basis as a pharmaceutical wholesaler handling BS products. We will also seek collaboration between AYUMI Pharmaceutical and KYOSOMIRAI PHARMA CO., LTD., a wholly owned subsidiary of TOHO HOLDINGS, and make concerted group-wide efforts to explore and cultivate new business areas.

2. Overview of AYUMI Pharmaceutical Corporation

(1) Company name	AYUMI Pharmaceutical Corporation
(2) Location	4-12-15 Ginza, Chuo-ku, Tokyo
(3) Representative	Kiyonori Karasawa, Chairman
(4) Business content	Manufacture and sale of medical drugs, including rheumatism drugs and analgesic antipyretics
(5) Capital	100 million yen
(6) Established	January 2015

3. Status of total number of shares acquired, acquisition price, total numbers of holding shares before and after the acquisition

(1) Total numbers of holding shares before the acquisition	0 share
(2) Total number of shares acquired	5,000,000 shares
(3) Acquisition price	Non-disclosure
(4) Total numbers of holding shares after the acquisition	5,000,000 shares (The Company's Voting Ownership: 20%)

4. Schedule

(1) Resolution by the Board of Directors	March 4, 2022
(2) Conclusion of agreement	March 8, 2022
(3) Transfer of shares	March 8, 2022

5. Forward looking outlook

While we expect that this transaction will have only a negligible impact on consolidated earnings and financial position of TOHO HOLDINGS, we believe that it will contribute to increase the Group's corporate value over the medium to long term. The Company will disclose any impact promptly if it becomes necessary to do so in the future.